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Vascular surgery has seen a revolutionary transformation in its approach to peripheral vascular disease over the last 2
decades, fueled by technological innovation and a willingness by the ﬁeld to adopt these changes. However, the under-
lying pathology behind critical limb ischemia and the signiﬁcant rate of unhealed wounds and secondary amputations
despite apparently successful revascularization needs to be addressed. In seeking to improve outcomes, it may be beneﬁcial
to examine our approach to vascular disease at the fundamental level of anatomy, the angiosome, to better dictate
reperfusion strategies beyond a simple determination of open vs endovascular procedure. We performed a systematic
review of the current literature concerning the signiﬁcance of the angiosome concept in the realm of vascular surgery. The
dearth of convincing evidence in the form of prospective trials and large patient populations, and the lack of a consistent,
comparable vocabulary to contrast study ﬁndings, prevent recommendation of the conceptual model at a wider level for
guidance of revascularization attempts. Further well-structured, prospective studies are required as well as emerging
imaging strategies, such as indocyanine green dye-based ﬂuorescent angiography or hyperspectral imaging, to allow wider
adoption of the angiosome model in vascular operations. (J Vasc Surg 2013;58:814-26.)Peripheral arterial disease (PAD) is increasing in preva-
lence worldwide affecting 12% to 20% of the elderly (aged
65 years and older).1 Critical limb ischemia (CLI) repre-
sents the most severe form of PAD and is characterized
by rest pain, ulcers, or gangrene.2 In patients who have
progressed to CLI, revascularization of the affected
extremity through surgical bypass or endovascular inter-
vention plays a crucial role in staving off limb loss, prolong-
ing survival, and improving their quality of life.3 Forty
percent of patients with CLI who lack revascularization
options face the prospect of major amputation within
1 year of diagnosis4,5; mortality in these patients may be
as high as 20% over this time.6
There is evidence to support either bypass surgery or
primary angioplasty as ﬁrst-line treatment modalities for
severe and critical limb ischemia.7 Traditionally, planning
for revascularization has utilized the ‘best vessel’ approach,
whereby the target outﬂow artery is chosen based on tech-
nical suitability, disease characteristics, length of bypass
required, conduit available, and patent distal vessel to
anchor the bypass.8,9 TASC II suggests that in the casethe Department of Vascular Surgery, Yale University School of
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tion, should be used. However, there is increasing interest
in the ‘angiosome model’ of revascularization for ischemic
ulceration.10-12
The angiosome concept was introduced 25 years ago in
a landmark paper by Taylor and Palmer.13 Utilizing ink
injection studies, dissection, perforator mapping, and
radiographic analysis of cadaveric specimens, the pair
deﬁned the angiosome as a three-dimensional network of
vessels not only in the skin, but in all tissue layers between
the skin and the bone. The primary supply to the skin was
found to come from direct cutaneous arteries, which vary
in diameter, length, and density in different areas of the
body. These are reinforced by small, indirect vessels that
tend to be the terminal branches of arteries that primarily
supply the deeper tissues. In the zone between adjacent
angiosomes,14 they identiﬁed reduced caliber (“choke”)
or similar caliber (“true”) anastomotic arteries that provide
redundant conduits to allow a given angiosome to receive
blood ﬂow from an adjacent neighboring angiosome if
the source artery is compromised. Ultimately, at least 40
angiosomes in the human body were characterized, with
six identiﬁed in the foot based on the three main arteries
to the foot (Fig 1).14,15ROLE OF DIRECT REVASCULARIZATION OF
AN AFFECTED ANGIOSOME
A systematic literature review was undertaken, using
search terms including ‘angiosome,’ ‘revascularization,’
‘critical AND limb AND ischemia,’ and ‘direct AND revas-
cularization’ (Fig 2). No date limit was set, and all papers
were fully accessed. Studies were included if they reported
results of the angiosome approach to revascularization of
ischemic lower limb ulceration by surgical, angioplasty, or
Fig 2. Summary of the article selection process.
Fig 1. The foot and ankle area are divided into six angiosomes, with one angiosome fed by the anterior tibial artery
(ATA), three by the posterior tibial artery (PTA), and two by the peroneal artery (PA). The ATA gives rise to the
dorsalis pedis artery, supplying the anterior compartment and dorsum of the foot (pink). The PTA gives rise to the
calcaneal branch, supplying the medial ankle (black) and plantar heel (green); the medial plantar branch, supplying the
medial instep (yellow); and the lateral plantar branch, supplying the lateral and plantar forefoot (blue). The PA supplies
the lateral ankle and plantar heel (red and green overlap) via the lateral calcaneal artery, and the anterior ankle via its
anterior perforator (pink overlap). Note the overlap of the heel by both the medial calcaneal branch of the PTA and the
lateral calcaneal branch of the PA.
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Table I. Treatment modality
First author
Year of
publication Country of study Study design
Number of limbs
(number of
patients)
Neville25 2009 USA Retrospective case series (consecutive
patients)
52 (48)
Varela20 2010 Spain Retrospective case series (consecutive
patients)
76 (70)
Iida20 2010 Japan Retrospective case series (consecutive
patients)
203 (177)
Deguchi23 2010 Japan Retrospective case series 66 (61)
Alexandrescu - SAVES21 2011 Belgium Retrospective case series 26 (25)
Alexandrescu17 2011 Belgium Retrospective case series 232 (208)
Azuma22 2012 Japan Retrospective case series (consecutive
patients)
218a (228)
Iida24 2012 Japan Retrospective case series (consecutive
patients)
369b (329)
Soderstrom19 2013 Finland Retrospective case series (consecutive
patients)
250 (226)
Kabra27 2013 India Prospective case series 64
Fossaceca26 2013 Italy Retrospective case series 201 (201)
aData from a subset analysis within larger study.
bForty-six patients included in previous study.
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in more than one paper, duplicate results were not
included.16 Data was collected on demographic informa-
tion including relevant comorbidities such as diabetes,
end-stage renal disease, and ischemic heart disease and
contributing factors such as smoking history and the pres-
ence of coexisting neuropathy. End points included limb
salvage, wound healing, mortality, technical success,
reintervention rate, time to ulcer healing, and major and
minor amputation. In studies that compared the use of
the angiosome-based direct revascularization (DR) with
nonangiosome-based indirect revascularization (IR), results
were taken to be signiﬁcant if P # .05.
Eleven articles were included in the outcomes analysis,
involving treatment of 1616 patients and 1757 limbs re-
ported in papers published between 2008 and 2013
(Table I). These studies were either retrospective case series
reviews or retrospective reviews of prospectively kept data-
bases. None of the studies were randomized controlled
trials. Techniques reviewed included surgical bypass only,
primary angioplasty only, hybrid procedures, or both
methods analyzed together. Some studies looked atprimary revascularization and excluded those patients
with previous interventions,17-20 while others described
the angiosome approach when used as a salvage procedure
in patients with previously failed attempts at revasculariza-
tion.21 Some studies looked retrospectively at the results of
patients in whom successful revascularization had been
undertaken, recording whether this had been achieved by
targeting the source artery supplying the affected angio-
some (equivalent to DR) or not.19,20,22-25 Other studies
compared the use of DR or IR in their patient series,
recording outcomes of each technique and thereby exam-
ining whether DR is technically possible and effective for
treatment of lower limb ischemic ulceration and, if so,
how it compares with the results of IR.18,21,26,27
Patient comorbidities were included in all studies
(Table II). Patients with diabetes were included in all
studies and were predominant in nine papers (>80%
patients with diabetes). Not all studies applied measures
to account for confounding factors. Five of 11 studies
included information on the topographical location of
disease. The most common site of tissue loss was the fore-
foot, including toes. Clinical assessment of ulceration was
Treatment modality (bypass
only, angioplasty only,
hybrid, both)
Procedure type
(primary, secondary, etc) Length of follow-up Outcomes assessed (timing of assessments)
Bypass Not speciﬁed Not speciﬁed Complete wound healing, time to
complete healing, major amputation,
mortality (100 days, 200 days)
Both (angioplasty as
ﬁrst-line if possible)
Primary procedure Median, 427 (175-828) days Healing time, healing rate, limb salvage,
major amputation, overall survival (1, 3,
6 months then every 6 months)
Angioplasty Primary procedure Up to 4 years Limb salvage, inﬂuence of run-off on limb
salvage (1, 2, 3, 4 years)
Bypass Not speciﬁed Median, 316 6 297 (DR)
381 6 312 (IR) days
Complete wound healing, time to wound
healing, major amputation
Hybrid e arteriovenous
switch
Unﬁt for, or previously
failed, conventional
treatment
Mean, 21.5 (1-62) months Technical success, patency, limb salvage,
wound healing, major amputation
(1, 6 months then every 6 months)
Angioplasty Primary procedure Mean, 38.6 (1-68) months Technical success, survival, freedom from
amputation, clinical success, patency,
wound healing (12, 24, 36 months)
Bypass Not speciﬁed Up to 24 months Wound healing rate, limb salvage (12,
24 months)
Angioplasty Not speciﬁed Mean, 18 6 16 months Limb salvage, death, reintervention rate,
amputation-free survival, freedom from
major adverse limb events, freedom from
major amputation
Angioplasty Primary Up to 1 year Ulcer healing rate, limb salvage, survival,
amputation-free survival, reinterventions
(1 month then every 1-3 months)
Both/hybrid Not speciﬁed Up to 6 months Ulcer healing, major amputation, death
(1, 3, 6 months)
Angioplasty Not speciﬁed Median 17.5 6 12 months Technical success, partial ulcer healing,
complete ulcer healing, restenosis, major
amputation, minor amputation, limb
salvage, TcPO2 (1, 6, 12 months then
every 6 months)
Table I. Continued.
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the Rutherford system (in seven studies), Wagner scale
(in two studies), the University of Texas Wound Classiﬁca-
tion System (in one study), and the Fontaine Stage (in one
study). Preprocedural measures of perfusion were speciﬁed
in eight studies, including toe pressure, ankle-brachial pres-
sure index (ABPI), skin perfusion pressure (SPP), or trans-
cutaneous oximetry (tcPO2). The presence of neuropathy
was documented in two studies, and presence of infection
was documented in four studies, but the deﬁnition of these
terms was unclear in one study (Table II).
TASC II classiﬁcation of disease severity was docu-
mented in four studies (Table III). Some studies con-
sidered only those patients with single crural vessel
run-off,20,27 one looked speciﬁcally at isolated below-the-
knee lesions,24 and others at multi-level disease including
aorto-iliac lesions.18 The target artery also varied, and
this was not reported consistently between studies.
The anterior tibial was the artery that most frequently fed
the affected angiosome, as reported in three studies. The
posterior tibial artery was most frequently targeted in DR
and IR (reported in four studies). The majority of studiesdid not specify the affected artery in terms of angiographic
ﬁndings, angiosome-based disease, or the targets used for
revascularization.
The clinical outcomes are summarized in Table IV.
Ten studies compared DR and IR. Of these, ﬁve reported
a signiﬁcant increase in limb salvage rate with DR when
compared with IR. Five out of eight studies who re-
ported wound healing rates found a signiﬁcant increase
with DR when compared with IR; however, length of
follow-up varied among these studies (Table I). Mean
time to healing was not signiﬁcantly different in DR
compared with IR when analyzed by three studies. One
study found a signiﬁcant increase in amputation-free
survival in DR when compared with IR (evaluated by
three studies24,26,27). One study that demonstrated
a signiﬁcant difference in wound healing at 12 months
with DR was undertaken by Varela et al,20 however,
this group also looked at the effect of collaterals on revas-
cularization. They further analyzed patients who had
undergone ‘IR through collaterals’ (ie, revascularization
of a nonfeeding artery that resulted in patent collaterals
to the affected area of ischemia), and this group achieved
Table II. Patient comorbidities
First author (year of publication)
Number
of patients Male Diabetes ESRD Smoker
Coronary
artery disease Hypertension
Presence of
neuropathy
Neville (2009)25 48 54% 87% 52% 36% 29% 39% Not speciﬁed
Varela (2010)20 70 59% 80% 4% 40% 29% 73% Not speciﬁed
Iida (2010)18 177 63% 68% 54% 31% 54% 82% Not speciﬁed
Deguchi (2010)23 61 78% 100% 59% Not speciﬁed 28% Not speciﬁed
Alexandrescu (2011) e SAVES21 25 72% 100% 57% Not speciﬁed 88% Not speciﬁed 88%
Alexandrescu (2011)17 208 71% 100% 42% 47% 85% 86% 84%
Azuma (2012)22 218 74% 81% 50% Not speciﬁed
Iida (2012)24 329 68% 73% 63% 27% 58% 78% Not speciﬁed
Soderstrom (2013)19 226 64% 100% 39% 21% 64% 76% Not speciﬁed
Kabra (2013)27 64 83% 82% 81% 16% 31% 60% Not speciﬁed
Fossaceca (2013)26 201 68% 100% 7% Not speciﬁed 32% 62% Not speciﬁed
ABPI, Ankle-brachial pressure index; ESRD, end-stage renal disease; CDC/NHSN, Center for Disease Control National Healthcare Safety Network; PSV,
peak systolic velocity; UTWCS, University of Texas Wound Classiﬁcation System.
Table III. Target vessel and technical results
First author
(year of
publication)
Methods of revascu-
larization (%)
Severity of lesions
(TASC II
classiﬁcation)
Feeding artery corresponding
to tissue loss using angiosome model DR: target vessel for intervention
AT PT Per AT PT Per
Neville (2009)25 Tibial bypass (100%) Not speciﬁed Not speciﬁed 50% 27% 23%
Verela (2010)20 Angioplasty (46%),
bypass to distal
popliteal artery or
belowa (54%)
Type B (1%),
Type C (7%),
Type D (92%)
DR: AT 82%; PT 13%; Per 4%
IR: AT 32%; PT 3%; Per 65%
P < .001; .23; <.001
82% 13% 4%
Iida (2010)18 Angioplasty (100%) Not speciﬁed DR: AT 55%; PT 44%; Pet 2%
IR: AT 58%; PT 46%; Per 2%
Aorto-iliacþstent
(12%), fem-pop (54%),
tibio-per (83%)
Deguchi
(2010)23
Paramalleolar bypass
(100%)
Not speciﬁed Not speciﬁed
Alexandrescu
(2011) -
SAVES21
Selective
ArterioVenous
Endoluminal
Switch (SAVES)
(100%)
Type B (7%),
Type C (23%),
Type D (69%)
46% 42% 12% 46%d 42% 12%
Alexandrescu
(2011)17
Below-the-knee
angioplasty (100%)
Type B (8%),
Type C (35%),
Type D (57%)
Not speciﬁed 25% 68% 7%
Azuma
(2012)g,22
Distal bypass (100%) Not speciﬁed Not speciﬁed Crural (63%), pedal (37%)
Iida (2012)g,24 Angioplasty (100%) TASC D (99%) Not speciﬁed Multiple targets
Soderstrom
(2013)g,19
Angioplasty (100%) Not speciﬁedf Not speciﬁed 61% 47% 24%
Kabra (2013)27 Bypass (56%),
angioplasty (39%),
hybrid (5%)
Not speciﬁed
Fossaceca
(2013)26
Below-the-knee
angioplasty
Not speciﬁed 41% 35% 24%
AT, Anterior tibial; DR, direct revascularization; IR, indirect revascularization; Per, peroneal artery; PT, posterior tibial.
aAll lesions treated by surgery were TASC-D.
bStudy only included primary procedures in which direct ﬂow to the foot was achieved through a single outﬂow vessel and remained patent during follow-up
without reintervention.
cIncluded only patients with successful revascularization: ‘obtaining ﬂow from more than one vessel to the pedal arch without surgical bypass.’
dVenosomes were targeted in this series.
eFailure ¼ vessel could not be reopened, mostly in TASC-D lesions.
fAngioplasty not performed in patients with TASC-D lesions unless unsuitable for bypass.
gResults are shown for propensity matched pairs.
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Severity of wounds
Indication for intervention
(all patients with non-healing ulceration) Presence of infection
Not speciﬁed ABPI <0.3, monophasic waveforms, TcO2 index <0.4 Not speciﬁed
UTWCS Grade 3 (50%) Ulcer >2 weeks duration, ABPI <0.5, monophasic
waveforms, toe pressure <50 mm Hg, lack of
pedal pulses
53% (according to CDC/NHSN
surveillance deﬁnition)
Rutherford 5 (71%) or 6 (29%) Ankle pressure <70 mm Hg, toe pressure <50 mm Hg,
SPP <40 mm Hg
Not speciﬁed
Rutherford 5 or 6; Wagner 3-4
(69%, complex 31%)
TcPO2 <30 mmHg, failed other attempts at
revascularisation
Not speciﬁed
Rutherford 6 (all); Wagner 1
(36%), Wagner 2-4 (64%)
Not speciﬁed 69% cellulitis >2 cm
Rutherford 5 (62%), Rutherford 6 (38%) Not speciﬁed
Rutherford 5 (73%) or 6 (27%) Toe pressure <50 mm Hg, SPP <40 mm Hg 39% on antibiotics
UTWCS Grade 3 (55%) ABPI mean 0.68, toe pressure mean 38 mm Hg UTWCS stage D (39%)
Rutherford 4 (2%), 5 (84%), 6 (14%) ABPI mean 0.5 Not speciﬁed
Fontaine Stage IV, Rutherford 5 or 6 TcPO2 <30 mm Hg, Doppler evidence signiﬁcant
stenosis (>70% caliber reduction, PSV >4 m/s)
Not speciﬁed
IR: target vessel
for intervention
DR: technical success/
primary patency
IR: technical
success/primary
patency DR: reintervention rate
IR:
reintervention rateAT PT Per
36% 36% 28% Not speciﬁed
IR attempted after failed DR N/Ab
Aorto-iliacþstent (19%),
fem-pop (53%), tibio-per (80%)
N/Ac
N/A Technical success
80%; primary
patency 66% at
12 months
N/A Not speciﬁed N/A
23% 65% 12% Technical successe
79%; primary
patency 59% at
12 months
Technical success
82%; primary
patency 61% at
12 months
Not speciﬁed
Crural (69%), pedal (31%) Not speciﬁed
Not speciﬁed
54% 18% 48% Not speciﬁed 15% 17%
Overall 95% technical success 10% re-angioplasty
within 12 months
18% re-angioplasty
within 12 months
Table II. Continued.
Table III. Continued.
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Table IV. Outcomes
First author
(year of
publication)
Number
of limbs
with DR (%)
Number
of limbs
with IR (%)
Limb salvage Wound healing rate complete healinga
DR IR P value DR IR P value
Neville (2009)25 27 (51) 25 (49) Not speciﬁed 91% 62% .03
Verela (2010)20 45 (59)b 31 (41) 93% at 24 months 72% at 24 months .02 92% at 12 months 73% at 12 months .008
Iida (2010)18 118 (58) 85 (42) 86% at 12 months 69% at 12 months .03 Not speciﬁed
Deguchi (2010)23 30 (45) 36 (55) Not speciﬁed 73% 72% .43
Alexandrescu
(2011) e
SAVES21
26 (100) 0 (0) 73% at 12 months N/A N/A 54% N/A
Alexandrescu
(2011)17
134 (64) 98 (47) 90% at 12 months 84% at 12 months .035 73% 69% .018
Azuma (2012)e,22 48 (50) 48 (50) 97.8% 92.3% .855 Not speciﬁed .185
Iida (2012)e,24 118 (50) 118 (50) 82% 68% .01 Not speciﬁed
Soderstrom
(2013)e,19
84 (50) 84 (50) 86% 77% .086 72% at 12 months 46% at 12 months .001
Kabra (2013)27 39 (61) 25 (39) 84% 75% .06 97% 83% .021
Fossaceca (2013)26 167 (83%)c 34 (17%) 90% at 17 6 12
months
91% at 17 6 12
months
NS 57% complete
healing at
12 months
32% complete
healing at
12 months
Not speciﬁed
DR, Direct revascularization (ie using the angiosome approach); IR, indirect revascularization (ie, not using the angiosome approach); NS, not signiﬁcant.
aHealing deﬁned as ‘complete epithelialization’ of wound.
bDR was considered gold standard.
cAll cases had initial attempts at DR; if failure due to chronic occlusion, suboptimal angioplasty, then IR was subsequently carried out.
dNo signiﬁcant difference in ‘effectiveness’ between DR and IR (ie, failure: major amputation, success: limb salvage); c2 value 0.02 at 12 months for a ¼ .05.
eResults are shown for propensity matched pairs.
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suggest that restoration of blood ﬂow to an area of
ischemic tissue via its collaterals, and not necessarily its
source artery, is also important. Although limb salvage
in this study was higher in DR than IR (93% vs 72%;
P ¼ .02), it was similar in DR and IR through collaterals
(93% vs 88%). Seven studies, with a predominantly dia-
betic population, reported limb salvage as a primary
outcome, and three found a signiﬁcant increase with
DR compared with IR.DETERMINING THE PERFUSION OF AN
ANGIOSOME
One of the critical issues that plague our under-
standing of the importance of the angiosome model is
how a vascular surgeon would determine the perfusion
of an affected angiosome in a patient with critical limb
ischemia. The studies performed to establish the
anatomic basis of the angiosome model were all con-
ducted in cadaveric samples.13,28-30 In these tissues,
perfusion of the arterial system with potentially toxic
substances to visualize the arterial branches was limited
only by the technical capacity of the investigators. Ink
studies, radio-opaque lead oxide dyes, and plastic injec-
tion were utilized to determine vascular anatomy and
end organ distribution. In living patients, methods
utilizing toxic materials and destructive tissue analysis
are obviously unavailable and undesirable. An ideal
system for angiosome mapping and imaging in the
vascular patient would be dynamic, easily utilized in
the interventional arena, with the capacity for real-time results and repeatability immediately before and
after a revascularization procedure.
The use of ultrasound has also been proposed as
a method toward mapping individual angiosomes in
speciﬁc patients. While the angiosome model holds that
the vascular distributions based on a source artery are
constant and predictable across all human subjects, the
extent of human variability within any given model is
well known to all surgeons. Attinger et al suggest that
the evaluation of the perfusion to a speciﬁc angiosome
may be based entirely on physical exam with the assistance
of a handheld Doppler device.15 After identifying an artery
supplying a given angiosome (source or collateral) by ultra-
sound, selective occlusion of the supplying artery above
and below the area can reveal the direction of ﬂow. The
character of the Doppler signal could also reveal the quality
of ﬂow in that segment. Though ultrasound may be useful
for mapping known territories, operational planning in
vascular surgery e especially in our current era of endovas-
cular intervention e often requires direct visualization of
the affected anatomy.
Recent breakthroughs in the use of dye material, laser
heat imaging, and angiography may provide the necessary
tools to make angiosome-guided revascularization effective
in real-time in the interventional setting. For example, Yin
et al perfused limbs with a carboxymethyl cellulose/lead
oxide injection then imaged by computed tomography
angiography and three-dimensional reconstruction.31 The
ﬁnal product yielded a highly detailed microvascular model
that clearly showed the vascular territory, spatial location,
distribution pattern, and anastomotic relationships of the
cutaneous perforators, as well as the source artery of the
Mean time to complete healing, days Amputation-free survival Major amputation Minor amputation
DR IR P value DR IR P value DR IR P value DR IR P value
164.4 159.8 .95 Not speciﬁed 9% 38% NS Not speciﬁed
71 91 .18 86% at 12 months 85% at 12 months .70 14% - all diabetic with non-healed wounds Not speciﬁed
Not speciﬁed
117 120 .95 Not speciﬁed 17% 25% .4 Not speciﬁed
NS N/A NS N/A 23% N/A Not speciﬁed
Not speciﬁed
Not speciﬁed
Not speciﬁed 49% at 4 years 29% at 4 years .0002 Overall 19% Not speciﬁed
Not speciﬁed 65% at 12 months 61% at 12 months .36 Not speciﬁed
Not speciﬁed 15% 16% Not speciﬁed
Not speciﬁed 10% 9% NSd 34% 62% NS
Table IV. Continued.
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work may include the discovery of additional ﬂap pedicles
on cadaveric study, the conceptual model may ultimately
be translatable to a clinical patient imaging system.
Fluorescent angiography through the use of indocya-
nine green dye (ICG) holds promise as a method of
real-time angiosome visualization in vascular surgery
both in and out of the operating room.32-34 Introduced
experimentally in the 1990s, ﬂuorescent angiography
came into regular use by plastic surgeons by the mid-
2000s. Based on ICG, a dye that absorbs in the near
infrared spectrum and emits in the visible spectrum, the
intraoperative system relies on a laser that allows immediate
visualization of tissue perfusion housed in an imaging
camera with a display monitor e a system akin to tradi-
tional ﬂuoroscopic angiography. Both ICG and the laser
have been proven safe to be used in humans; the low-
level laser does not require the use of protective goggles
by the operating staff. ICG has the advantages of being
excreted exclusively by the liver into the biliary system,
allowing for use in renal-compromised patients, having
a short half-life (3-5 minutes), being conﬁned to the intra-
vascular compartment due to its plasma protein binding
proﬁle, and rarely produces anaphylactic reactions. As
ICG contains iodide, its use should be avoided in patients
with this sensitivity. Fluorescent angiography is sensitive
enough to illustrate small vessels and it has been used to
track inﬂow, outﬂow, and runoff from a reconstructive
ﬂap and its microscopic anastomoses, as well as delineating
the borders of angiosomes used in ﬂap design.35 Whether
the adoption of ﬂuorescent angiography in vascular surgery
is a viable strategy toward guiding arterial reconstructionhas yet to be determined, although preliminary assessments
have been promising.32,33 A worthwhile comparison could
be to compare pre- and postrevascularization values within
the angiosome concerned in direct and indirect vasculariza-
tion groups to achieve perfusion data (Fig 3). Certainly, the
advantages of real-time assessment of perfusion and intrao-
perative repeat assessment are attractive features of the
system.
Hyperspectral imaging has emerged as another poten-
tial tool to allow us to perform real-time assessment of the
target angiosome for reperfusion as well as the effectiveness
of the arterial reconstruction. Hyperspectral imaging
utilizes scanning spectroscopy using wavelengths of visual
light to construct spatial maps of tissue oxygenation
(Fig 4). Having the advantages of being noninvasive,
nonionizing, and noncontact, it has also been shown to
detect changes in skin microcirculation in diabetics and
to able to predict healing of diabetic foot ulcers with a sensi-
tivity of 86% and speciﬁcity of up to 88%. Chin et al found
measurable differences in tissue oxygenation of 222 limbs
along angiosomal distributions between patients with and
without PAD.36 Measuring deoxyhemoglobin values in
the plantar metatarsal, heel, and arch angiosomes, signiﬁ-
cant differences were found to be correlated not only
with PAD status, but severity of PAD as measured by
ABPI and Doppler ultrasound waveforms.
With the development of real-time strategies to deter-
mine the best target for appropriate revascularization as
well as the adequacy of the restored inﬂow, emerging tech-
nologies hold promise in reﬁning surgical and interven-
tional efﬁcacy in vascular surgery, especially when
considering the angiosome theory. These technologies
Fig 3. Quantitative assessment of local perfusion using indocyanine green (ICG) ﬂuorescence imaging (Photodynamic
Eye, Hamamatsu, Japan). Measurements are made from the video sequence with maximum intensity: A,Measurements
1 day before and 1 day after bypass from femoral to distal anterior tibial artery and amputation of 4th and 5th toes. B,
Measurements 1 day before and 1 day after multilevel PTA on superﬁcial femoral and popliteal artery as well on
tibioperonel trunk and peroneal artery. PTA, Percutaneous transluminal angioplasty; PDE10, ﬂuorescence intensity at
10 seconds from the rising point of the intensity curve, measurements from selected spots of interest (with tcpO2
measurements as reference); T½, time to reach the half of the maximum ﬂuorescence intensity.
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Fig 4. Assessment of plantar angiosome perfusion utilizing hyperspectral imaging. The visual, integrated
oxyhemoglobin-deoxyhemoglobin, and only deoxyhemoglobin hyperspectral images are shown of the plantar meta-
tarsal angiosome for a foot with no PAD (left) and a foot with PAD (right). The foot with PAD demonstrates
substantially decreased oxyhemoglobin and deoxyhemoglobin values throughout the angiosome. (Images courtesy of
Jason Chin and Melina Kibbe.) PAD, Peripheral arterial disease.
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and easily used modality for vascular assessment for use in
the interventional setting.
DISCUSSION
The gold standard in vascular surgery for critical limb
ischemia has traditionally been bypass surgery. For patients
in whom bypass was deemed improbable e for example,
due to the lack of a target vessel or adequate outﬂow e
advancements in treatment have been made possible with
the advent of endovascular interventional techniques in
restoring arterial ﬂow.
Contemporary attempts at revascularization are tradi-
tionally directed towards the ‘best artery’ for bypass or
angioplasty; however, several modern revascularization
series report a rate of unhealed ischemic wounds despite
patent bypass or recanalized in-line ﬂow to the foot in up
to 18% of cases, leading to a secondary amputation.8,37,38
These sobering statistics have fueled interest in the
angiosome-based strategy, whereby ﬂow is directed to
the area of ischemic ulceration via its source artery, rather
than focusing on the most suitable artery to be targeted.
Our systemic review of available literature demon-
strates that there is limited data available to substantiate
an angiosome-based model of revascularization. We were
only able to identify ﬁve studies that report a signiﬁcant
increase in limb salvage and wound healing when
comparing DR with IR. All studies were retrospective
and exhibit heterogeneity of patient characteristics and
outcomes, precluding accurate comparison, despite
attempts to control confounders by propensity score anal-
ysis.19,22 Limitations of the angiosome approach included
technical feasibility, reproducibility between centers, and
the application of ﬁrst principles to a heterogeneous popu-
lation of patients with ischemic ulceration, in particular,
those with diabetes and a variable collateral blood supply.
Wound healing is slower in patients with diabetes and
end-stage renal disease,39 and there is a tendency for
poor collateralization40 due to the deterioration of small
and medium-sized arteries.13 Furthermore, healing of dia-
betic foot ulcers is worsened by microvascular dysfunction
caused by neuropathy as well as the severity of infec-
tion.41,42 This adds further complexity to the management
of ischemic ulceration, particularly when considering tar-
geted treatment of vascular territories. It also underscores
the utility of the peroneal artery as target, since it anasto-
moses via its anterior perforating branch with the anterior
lateral malleolar artery of the dorsalis pedis and also to
the posterior tibial artery via transverse communicating
branches at the level of the Achilles tendon. O’Neal
described the ‘diabetic end-artery occlusive disease theory,’
suggesting that the combination of patchy atherosclerotic
lesions, acute septic thrombosis, and destruction of collat-
erals may explain why irrigation of variable areas of the dia-
betic foot may rely on a single speciﬁc source artery.43
Perhaps, then, it is even more pertinent to target revascu-
larization to the source artery supplying an area of ischemic
ulceration in patients with diabetes, who will have anobliterated collateral network.28 There is escalating interest
in this area.10,44 However, caution needs to be exercised
that direct revascularization attempts into a speciﬁc angio-
some should not supersede good surgical judgment.
In order to evaluate the angiosome concept of revascu-
larization, larger studies are required. In the ﬁrst instance,
comparison of wound topography and the theoretical
angiosome-based targets for revascularization with angio-
graphic patterns of disease may help identify whether it is
technically possible to use a DR approach to revasculariza-
tion in an unselected population. Importantly, the impact
of diabetes on collateral supply, speciﬁcally the pedal
arch, and angiosome boundaries should be documented
and explored. Following from this, clinical and technical
outcomes of DR vs IR should be evaluated in multi-
center studies, with clearly speciﬁed standardized outcomes
and end points such as wound healing or amputation-free
survival.
Finally, it must also be stated that the multi-disciplinary
approach, including serial debridement, treatment of sepsis,
and risk factors, must also be employed when treating
patients with ischemic ulceration.45 The presence of local
neuropathy in patients with diabetes is also an important
factor to consider e autonomic denervation contributes
to microvascular impairment and impaired wound healing,
even in the presence of patent arteries. Adequate control of
these factors should be considered imperative. This was
variably reported among the studies analyzed.CONCLUSIONS
The clinical relevance of the angiosome concept may
not be fully determined until randomized controlled trials
are conducted. Unfortunately, the gold standard of
a randomized controlled trial may not be ethical in these
patients, as the selection of a distal target in surgical bypass
and endovascular therapy must be dictated by best surgical
principles, and not by a research directive that would
command an inferior intervention. Furthermore, it would
be very difﬁcult to build up truly comparative patient
groups, and thus any properly planned randomized trial
would have a low external value. Thus, more clinical
evidence in the form of well-structured, prospective studies
must be available before widespread adoption as a novel
technique in vascular reconstruction can be advocated.AUTHOR CONTRIBUTIONS
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